Flotation Recovery Tests of Silver Minerals from a Cyanide Slag in Colombia by Shuibo CHEN, Qiankun WANG, Zhongmei SUN, Yuyun SU, Qihong XU

“…This is an article in the field of mineral processing engineering. The process of “SABC grinding – gravity separation – cyanidation leaching – INCO detoxification” were conducted on the gold ore in Colombia. …”
Get full text

Road Transport and Urban Mobility Greenhouse Gas Emissions Factor for Air Pollution Modeling in Burkina Faso by Issaka Abdou Razakou Kiribou, Tiga Neya, Bernard Nana, Kehinde Ogunjobi, Tizane Daho, Y․ Woro Gounkaou, Faith Mawia Muema, Dejene W. Sintayehu

Get full text

益肾汤联合强的松与依那普利对IgA肾病小鼠肾 MMP-965380;TIMP-1表达的影响

“…【目的】探讨中药“益肾汤”治疗IgA肾病(IgAN)的机理65377;【方法】用“口服牛血清白蛋白联合尾静脉注射葡萄球菌肠毒素B”法复制小鼠IgAN模型65377;设正常组65380;模型组65380;益肾汤低浓度65380;益肾汤高浓度65380;强的松+依那普利65380;强的松+依那普利+益肾汤低浓度65380;强的松+依那普利+益肾汤高浓度7组65377;FQ*9鄄PCR法检测小鼠肾组织MMP*9鄄965380;TIMP*9鄄1mRNA表达65380;免疫组化SABC法检测小鼠肾组织MMP*9鄄965380;TIMP*9鄄1的含量65377;【结果】模型组小鼠肾间质MMP*9鄄9表达(PU值:6.9 ± 2.7 vs 5.8 ± 2.1;mRNA表达:0.297 ± 0.025 vs 0.107 ± 0.004)与正常组比较差异无显著性(P > 0.05),而模型组TIMP*9鄄1表达(PU值:18.0 ± 7.7 vs 5.2 ± 2.2;mRNA表达:0.884 ± 0.247 vs 0.109 ± 0.007)则较正常组明显上调(P < 0.05)65377;益肾汤低浓度组与高浓度组之间肾小管间质MMP*9鄄965380;TIMP*9鄄1表达差异无显著性(P > 0.05),但益肾汤高浓度组与低浓度两组MMP*9鄄9表达均强于模型组(PU值:8.9 ± 3.0 vs 6.9 ± 2.7,8.9 ± 3.3 vs 6.9 ± 2.7;mRNA表达:0.397 ± 0.047 vs 0.297 ± 0.025,0.386 ± 0.027 vs 0.297 ± 0.025;P < 0.05),而TIMP*9鄄1的表达均弱于模型组(PU值:14.92 ± 6.07 vs 18.04 ± 7.70,15.55 ± 6.01 vs 18.04 ± 7.70;mRNA表达:0.665 ± 0.197 vs 0.883 ± 0.247,0.713 ± 0.221 vs 0.883 ± 0.247;P <0.05)65377;5个治疗组中强的松+依那普利+益肾汤高浓度组MMP*9鄄9 mRNA及其蛋白表达最强(PU值:34.3 ± 8.7;mRNA表达:1.265 ± 0.433)65380;而TIMP*9鄄1mRNA及其蛋白表达最弱(PU值:9.2 ± 3.4;mRNA表达: 0.293 ± 0.068)65377;【结论】益肾汤可促进IgAN小鼠肾组织MMP*9鄄9的表达65380;抑制TIMP*9鄄1的表达65377;强的松+依那普利+益肾汤的联合治疗方案较单用强的松+依那普利或单用益肾汤治疗IgAN有更好的疗效65377;…”
Get full text

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer by Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis

“…A comprehensive search of PubMed/MEDLINE, EMBASE, Cochrane Central, and select conference abstracts (i.e., AACR, ASCO, SABCS, ECCO, and ESMO conferences between 2014 and 2017) identified 39 studies of patients with HR+, HER2– mBC. …”
Get full text

Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis by Roberto Buonaiuto, Aldo Caltavituro, Margherita Tafuro, Alessandra Longobardi, Giuliana Pavone, Pierluigi De Santis, Roberta Caputo, Carmine De Angelis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Martina Pagliuca, Michelino De Laurentiis

“…Methods: We conducted a meta-analysis including the most recent randomized trial data systematically searched from PubMed, Embase, Web of Science, Cochrane CENTRAL (from inception to May 31st, 2024) or presented in abstracts or oral presentations at the ESMO, ASCO, and SABCS international congresses. We included studies comparing CDK4/6i (palbociclib, ribociclib, abemaciclib, dalpiciclib) + ET versus placebo + ET. …”
Get full text